NCT00769587

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Phase II Study of Thalidomide in Mastocytosis

• Status: Completed
• Phase: —
• Study type: Interventional
• Enrollment: —
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.

Detailed description

OBJECTIVES: Primary * Determine the objective response rate at 6 months in patients with systemic mastocytosis treated with thalidomide. Secondary * Determine the tolerability of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive oral thalidomide once daily for 6 months in the absence of disease progression.

Conditions

• Non Neoplastic Condition
• Precancerous Condition

Interventions

Type	Name	Description
DRUG	thalidomide

Timeline

• Start date: 2007-06-01
• Primary completion: 2011-05-01
• Completion: 2012-10-01
• First posted: 2008-10-09
• Last updated: 2025-09-22

Locations

1 site across 1 country: France